18 Participants NeededMy employer runs this trial

VY1706 for Early Alzheimer's Disease

V
Overseen ByVoyager
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Voyager Therapeutics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Are You a Good Fit for This Trial?

This trial is for adults aged 55–80 with early Alzheimer's disease or mild cognitive impairment, who are otherwise in good health. People with a family history of inherited Alzheimer's can join from age 30. Participants must have stable medications and a reliable study partner.

Inclusion Criteria

I am between 55 and 80, or 30 and 80 with a known inherited Alzheimer's mutation.
I have mild memory loss or early Alzheimer's disease.
I have been on a stable dose of my Alzheimer's medication for at least 8 weeks.
See 4 more

Exclusion Criteria

I have a history of serious heart or blood vessel disease.
I have HIV, hepatitis C, or current hepatitis B infection.
History within 1 year prior to screening of drug or alcohol abuse
See 9 more

What Are the Treatments Tested in This Trial?

Interventions

  • VY1706 High Dose
  • VY1706 Low Dose
  • VY1706 Mid Dose

Trial Overview

The study tests different doses (low, mid, high) of a new drug called VY1706 to find the safest dose for people with early Alzheimer's disease. It also includes blood tests to monitor immune response.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Mid dose IV InfusionExperimental Treatment2 Interventions
Group II: Low dose IV InfusionExperimental Treatment2 Interventions
Group III: High dose IV InfusionExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Voyager Therapeutics

Lead Sponsor

Trials
6
Recruited
110+